Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning ...

The global lipid nanoparticles market is on track to grow from USD 271.8 million in 2024 to USD 350.5 million by 2029, driven ...

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Corp. with ...

We recently published a list of 10 Best Healthcare Stocks To Buy According to Hedge Funds. In this article, we are going to ...

AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and ...

Pfizer's foundation remains solid, based on strong cash flows generated from a basket of diverse drugs. The company's large size confers significant competitive advantages in developing new drugs.

It’s similar with multiple sclerosis. Actually, there are so many good drugs out there. A lot of the market has already been ...

The Global Infectious Disease Therapeutics Market is projected to grow at a CAGR of 5% from 2024 to 2030, according to a new report ...

Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.

NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir ... published in The Journal of Infectious Diseases and further supports the... Merck , known as MSD ...

The health news update discusses Washington state's abortion pill stockpile as a safeguard, BioAge's successful IPO, a ...